3 Apr 2018 07:00
3 April 2018
Proteome Sciences plc
("Proteome Sciences" or the "Company")
License Agreement Extension with Thermo Fisher Scientific
Electrophoretics Ltd, a wholly owned subsidiary of Proteome Sciences plc, is pleased to announce that it has signed an amendment to the exclusive License and Distribution Agreement with Pierce Biotechnology Inc., a part of Thermo Fisher Scientific Inc., extending the current license to include intellectual property relating to a new class of higher-plex TMT® reagents currently in development. Such higher-plex technology represents the next phase in the evolution of isobaric tagging and will enable further advances in the efficiency and utility of mass spectrometric protein analyses.
Jeremy Haigh, Chief Executive Officer of Proteome Sciences plc, commented: "We are delighted to extend our successful and exclusive collaboration with Thermo Fisher Scientific through which TMT® has become the market leader and established standard for multiplex, quantitative proteomic experiments. The development of higher-plex TMT® reagents has been a long-standing objective for Proteome Sciences and we look forward to continuing our partnership with a recognised world leader in serving science and innovation."
For further information:
Proteome Sciences plc | |
Jeremy Haigh, Chief Executive Officer | Tel: +44 (0)20 7043 2116 |
Ian Pike, Chief Scientific Officer | |
finnCap Limited (Nominated Adviser & Broker) | |
Geoff Nash/James Thompson Abigail Wayne (Broking) | Tel: +44 (0)20 7220 0500
|
About Proteome Sciences plc. (www.proteomics.com)
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented several novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
This announcement contains inside information for the purpose of Article 7 of EU Regulation 596/2014
Proteome (PRM)